Rigel Pharmaceuticals RIGL Current portion of mortgage and loans payable
Current portion of mortgage and loans payable at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LoansPayableCurrent.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's current portion of mortgage and loans payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's current portion of mortgage and loans payable?
- Rigel Pharmaceuticals (RIGL) reported current portion of mortgage and loans payable of $29.87M in Q1 2026.
- How has Rigel Pharmaceuticals's current portion of mortgage and loans payable changed year-over-year?
- Rigel Pharmaceuticals's current portion of mortgage and loans payable increased by 101.6% year-over-year, from $14.82M to $29.87M.
- What is the long-term trend for Rigel Pharmaceuticals's current portion of mortgage and loans payable?
- Over 2 years (2023 to 2025), Rigel Pharmaceuticals's current portion of mortgage and loans payable has grown at a 103.1% compound annual growth rate (CAGR), from $7.23M to $29.81M.
- What does current portion of mortgage and loans payable mean?
- This represents the portion of debt obligations, including principal repayments on loans, that are due within the next twelve months. It serves as a key indicator of the company's short-term liquidity and its ability to meet immediate debt service requirements. A high ratio of current debt to total assets may signal potential refinancing risks.